Chemo-radiation plus immunotherapy for low rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests adding an immunotherapy drug (QL1706) to standard chemotherapy and radiation before surgery for low rectal cancer. The goal is to see if this combination can shrink tumors more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with low rectal cancer (tumor within 7 cm of the anal opening) that has not spread to other organs.
- You are willing to receive treatment before surgery (chemotherapy, radiation, and immunotherapy).
- You have a good overall health status (ECOG score 0 or 1).
- Your blood counts and organ function are within acceptable ranges.
- You are able to attend follow-up visits as needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
This trial tests whether adding a new immunotherapy drug (cadonilimab) to standard chemoradiation before surgery helps patients with locally advanced rectal cancer. It aims to improve treatment outcomes by using a shorter course of radiation followed by a combination of the immunotherapy and chemotherapy.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This trial tests a combination of short-course radiation, chemotherapy (CAPOX), and an immunotherapy drug (PD-1 inhibitor) for people with high-risk locally advanced rectal cancer. The goal is to see if this approach can improve outcomes before surgery.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.